Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Q2 2010 Earnings Presentation
12 slides from Swedish Orphan Biovitrum Ab's earnings presentation, Jul 20, 2010
Slide 1: Second Quarter 2010
Second Quarter 2010 2010-07-20
Slide 2: Disclaimer
DISCLAIMER In order to utilize the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing the following cautionary statement. This presentation contains forward- looking statements with respect to the financial condition,
Slide 3: Q2 2010 – Strong sales growth in the US
Q2 2010 – Strong sales growth in the US • Revenues amounted to SEK 510 M • Revenues, excluding Tracleer, increased by 9% in CER and by 3% in SEK • Sales in North America increased by 38% in CER, and by 32% in SEK • Sales in Europe, excluding Tracleer, increased by 3% in CER, corresponding to -6% in
Slide 4: Q2 2010, and after the period - Important R&D progress and business deals
Q2 2010, and after the period - Important R&D progress and business deals • Exclusive rights to Ruconest® for Hereditary Angioedema (HAE) received for 24 EU countries as well as in Norway, Iceland and Switzerland • Decision to advance Kiobrina® into a phase III development Events after the period •
Slide 5: Q2 2010 – Revenues up 9% and EBITA up 13%, despite EU price pressure
Q2 2010 – Revenues up 9% and EBITA up 13%, despite EU price pressure Apr 1 - Jun 30 Jan 1 - Jun 30 Full year Pro forma Pro forma Amounts in SEK million 2010 2009 2009 2010 2009 2009 2009 Total revenues, Constant Exchange Rate 535,9 319,9 510,9 1 060,2 675,1 1 054,1 1 297,0 Total revenues, reported 5
Slide 6: Q2 2010 - Sales Kineret up 10% and Orfadin up 15%
Q2 2010 - Sales Kineret up 10% and Orfadin up 15% Apr 1 - Jun 30 Jan 1 - Jun 30 reported CER reported CER Amounts in SEK million 2010 2010 2009 2010 2010 2009 ReFacto® 177,6 179,6 167,4 304,8 311,0 370,5 of which Manufacturing revenues 117,8 117,8 95,1 190,9 190,9 231,7 of which Co-promotion 22,6 23
Slide 7: Q2 2010 - US sales up 38% (25 % in H2 2010)
Q2 2010 - US sales up 38% (25 % in H2 2010) Apr 1 - Jun 30 Jan 1 - Jun 30 reported CER reported CER Amounts in SEK million 2010 2010 2009 2010 2010 2009 Nordic 80,5 83,7 95,9 167,3 173,7 189,2 Europe 135,6 151,3 150,2 285,2 315,1 291,7 North America 98,9 103,7 74,8 173,7 191,0 152,3 RoW 5,4 5,0 8,9
Slide 8: Strong and low risk emerging development pipeline
Strong and low risk emerging development pipeline Indication Product/Project Partner Phase I Phase II Phase III Reg phase Hemophilia B rFIXFc BiogenIdec Hemophilia A rFVIIIFc BiogenIdec Fat malabsorption in premature infants Kiobrina® Fat malabsorption Exinalda® Rh-Immunization Sym001 Symphogen Auto
Slide 9: Development news flow
Development news flow Activity Expected completion rFVIIIFc (hemophilia A): phase III, first patient in (FPI) H2 2010 Sym001 (ITP): phase II study H2 2010 Kiobrina® (fat malarbsorption): phase III, (FPI) H1 2011 rFIXFc (hemophilia B): phase III 2011/2012 9
Slide 10: Outlook 2010 and long term objectives unchanged
Outlook 2010 and long term objectives unchanged • The company continues to closely monitor the uncertainty in the European pharmaceutical market • Operating income (EBITA) expected to increase 30-35% in CER • Revenue growth of 8-10% in CER • Gross profit margin expected to be between 63-65% • Operat
Slide 11: Q2 2010 Summary – Platform for near and long term profitable growth strengthened
Q2 2010 Summary – Platform for near and long term profitable growth strengthened • Revenues increased by 9% in CER driven by growth products • EBITA grew by 13% in CER • Important addition to the product portfolio further strengthens the growth platform • Successful business deal with Chinese partne
Slide 12: www.sobi.com
@sobdl SWEDISH ORPHAN BIOVITRUM www.sobi.com 2010-07-20
Swedish Orphan Biovitrum — Q2 2010 Earnings Presentation on 6ix